31 January 2012
Early Bird Registration Rate Extended until February 10th 2012.
Due to demand we have extended our Early Bird registration rate for 10 days until Friday, February 10th 2012. This means you can save nearly £100 when registering for the full three days.
P2T 2012 is an interdisciplinary three day conference in Glasgow bringing together international experts to share knowledge and experience with the aim of accelerating Progress to Therapy in Regenerative Medicine.Don't miss out, register your place now.
11 January 2012
Dr Joseph F Amaral (Johnson and Johnson) Confirmed for P2T 2012
Vice President of Surgical Technology and Science at Johnson and Johnson, Dr Amaral is internationally recognized as a pioneer in laparoscopic surgery.
Most recently, Dr Amaral was President and CEO of Rhode Island Hospital (RIH) and its pediatric division Hasbro Children’s Hospital from 2000 to 20007 and also served as its COO for 3 1/2 years. During this period, he led a financial turnaround while at the same time investing over $450 million in renovation projects, new technologies and new facilities and tripling externally funded research.
Dr Amaral was instrumental in the success of Ultracision, a start-up company, by developing the company CEO Tom Davison, Ph.D., the Harmonic Scalpel, the first and still leading ultrasonically activated cutting and coagulating surgical device. He has served as a consultant, advisory board member and board member to multiple leading healthcare biotech and start-up companies.
He is Professor of Surgery at Brown University School of Medicine, member of 25+ professional societies, author of 80+ papers and book chapters and has delivered 250+ national and international presentations.
Most recently, Dr Amaral was President and CEO of Rhode Island Hospital (RIH) and its pediatric division Hasbro Children’s Hospital from 2000 to 20007 and also served as its COO for 3 1/2 years. During this period, he led a financial turnaround while at the same time investing over $450 million in renovation projects, new technologies and new facilities and tripling externally funded research.
Dr Amaral was instrumental in the success of Ultracision, a start-up company, by developing the company CEO Tom Davison, Ph.D., the Harmonic Scalpel, the first and still leading ultrasonically activated cutting and coagulating surgical device. He has served as a consultant, advisory board member and board member to multiple leading healthcare biotech and start-up companies.
He is Professor of Surgery at Brown University School of Medicine, member of 25+ professional societies, author of 80+ papers and book chapters and has delivered 250+ national and international presentations.
Dr Amaral will be discussing 'Clicnical Trials to
Reimbursement' as part of one of our workshops on Day Three.
Subscribe to:
Posts (Atom)